 CAMBRIDGE, Mass., April 28, 2021 GLOBE NEWSWIRE -- Trillium Therapeutics Inc. NASDAQTSX: TRIL, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first multiple myeloma patient with TTI-622 SIRPα-IgG4 Fc, an investigational checkpoint inhibitor of the innate immune system, in combination with the proteasome inhibitor carfilzomib and dexamethasone. 